Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

VEGFD (VEGF4) (AA 89-205) Antikörper

Reaktivität: Human IHC (p), WB Wirt: Kaninchen Polyclonal unconjugated
Produktnummer ABIN4953063
  • Target
    VEGFD (VEGF4)
    Bindungsspezifität
    • 1
    • 1
    AA 89-205
    Reaktivität
    Human
    Wirt
    • 1
    Kaninchen
    Klonalität
    • 1
    Polyklonal
    Konjugat
    • 1
    Unkonjugiert
    Applikation
    Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB)
    Aufreinigung
    Antigen affinity
    Immunogen
    Amino acids 89-205 of human VEGFD were used as the immunogen for the VEGFD antibody.
    Isotyp
    IgG
  • Applikationshinweise
    Optimal dilution of the VEGFD antibody should be determined by the researcher.\. Western blot: 0.1-0.5 μg/mL,IHC (FFPE): 1-2 μg/mL
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Buffer
    0.5 mg/mL if reconstituted with 0.2 mL sterile DI water
    Lagerung
    -20 °C
    Informationen zur Lagerung
    After reconstitution, the VEGFD antibody can be stored for up to one month at 4°C. For long-term, aliquot and store at -20°C. Avoid repeated freezing and thawing.
  • Target
    VEGFD (VEGF4)
    Andere Bezeichnung
    VEGFD / VEGF4
    Hintergrund
    C-fos induced growth factor (FIGF) (or vascular endothelial growth factor D, VEGFD, VEGF4) is a vascular endothelial growth factor that in humans is encoded by the FIGF gene. The protein encoded by this gene is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family and is active in angiogenesis, lymphangiogenesis, and endothelial cell growth. Analyzing by Northern blotting, Yamada et al. (1997) symbolized VEGFD, was expressed as a 2.2-kb transcript with highest expression in lung, heart, small intestine, and fetal lung, and lower levels in skeletal muscle, colon, and pancreas. And Achen et al. (1998) concluded that VEGFD was most closely related to VEGFC by virtue of the presence of N- and C-terminal extensions that were not found in other VEGF family members. Stacker et al. (2001) showed that VEGFD can induce tumor angiogenesis through VEGFR2 and tumor lymphangiogenesis through VEGFR3, whereas VEGF, which does not activate VEGFR3, induces only tumor angiogenesis.
    UniProt
    O43915
Sie sind hier:
Kundenservice